Latest News
ICYMI: IGT Chair Erik Paulsen and Scientific, Academic and Medical Council Chair Donna M. Christensen on the Future of Gene Therapy
The Federal Newborn Screening Program at a Crossroads
What Newborn Screening Really Means in the Sickle Cell Disease Community and Beyond
IGT Patient Advocacy Advisory Council Members Recognize Newborn Screening Awareness Month
IGT Joins House Budget Committee Health Care Task Force Roundtable on Cell and Gene Therapies
IGT, ARM Congressional Briefing Highlights: MDRP Proposed Changes Threaten Patient Access to Care
Congressional Briefing: Realizing the Promise of Gene Therapy: Protecting Patients & Innovation
IGT Statement on Senate Introduction of the MVP Act
Health Care’s Genetic and Cellular Transformation Must Benefit All Patients in Need
IGT Responds to HRSA RFI on Nomination and Evidence-Based Review Process of the Advisory Committee on Heritable Disorders in Newborns and Children
IGT Recognizes National Minority Health Month (NMHM)
AEI Panel Discussion: Navigating Emerging Technologies in Cell and Gene Therapy
IGT Responds to Senator Bill Cassidy’s RFI on Improving Americans’ Access to Gene Therapies
Congressional Briefing: Realizing the Promise of Gene Therapy: Ensuring Access
Year In Review: Gene Therapies Make a Big Splash in 2023
ASGCT Policy Summit Brings Together Stakeholders to Address Access Issues
Congressional Briefing: Realizing the Promise of Gene Therapy: Ensuring Access
ICYMI: Gene therapy provides hope for Huntington’s Disease patients
What They’re Saying: Strong Support for the MVP Act
IGT Congressional Letter and Statement on the Re-Introduction of the MVP Act (H.R. 2666)
Perspective: Advancing Hope for Andrew and Countless Others
Our Healthcare Policies Must Account for the True Value of Transformative Gene Therapies
Congressional Briefing: Realizing the Promise of Gene Therapy through Science & Policy
ICYMI: Cure Sickle Cell Disease by 2030?
A Bold Goal to Cure Sickle Cell Disease by 2030
IGT Comments on CMS Fiscal Year 2023 Medicare Inpatient Prospective Payment Systems Proposed Rule
New Resource: Understanding the Complexity of Gene Therapy Science & Manufacturing
IGT Chairman Erik Paulsen Joins Healthy Future Task Force Treatments Subcommittee Roundtable
A Troubling Policy Proposal
Prioritizing Minority Health
IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)
Rare Disease Day Spotlight: Hope for HPP Patients
Changing the Way We Look at Huntington’s Disease
IGT Statement on CMS Final Rule on Medicaid Value-based Purchasing Arrangements
IGT Statement on Senate's FY2022 Appropriations Bill
Patient Perspective: Khrystal Davis
Howard University’s Dr. Sudha Sharma on the Importance of Addressing Health Inequities
IGT Statement on ICER’s Analysis of the Accelerated Approval Pathway
The Importance of National Minority Health Month
NEW IGT Policy Resources Available
IGT Recognizes Rare Disease Day
IGT Comments on CMS Final Rule on Value-based Purchasing Arrangements
Patient Perspective: Erin Frey with CureDuchenne
Patient Perspective: Cure SMA
Dr. Peter Marks Clarifies FDA’s Approach to Gene Therapies After CRL for Hemophilia A Treatment
Patient Perspective: EveryLife Foundation for Rare Diseases
IGT Comments on CMS Proposed Rule on Value-based Purchasing Arrangements
IGT Webinar on CMS Proposed Rule on Value-based Purchasing
IGT to Host Webinar on CMS Proposed Rule on Value-based Purchasing
IGT Statement on CMS Proposed Rule to Facilitate Value-based Purchasing Arrangements